Disc Medicine, Inc
Clinical trials sponsored by Disc Medicine, Inc, explained in plain language.
A clinical-stage biotech developing treatments for hematologic diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug bitopertin offers hope for sunlight pain relief in rare blood disorders
Disease control ENROLLING_BY_INVITATIONThis long-term study tests the safety and effectiveness of bitopertin (DISC-1459) in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight exposure. About 230 participants who previously took bitoper…
Phase: PHASE2, PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could let Sun-Sensitive patients enjoy the outdoors
Disease control OngoingThis Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. …
Phase: PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to reduce Blood-Letting in rare blood cancer
Disease control OngoingThis study tests an experimental drug called DISC-3405 in 60 adults with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to see if the drug can safely lower the need for phlebotomies (blood removal) and control blood counts. Participants …
Phase: PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC